Skip to main content

Table 3 Laboratory scale cranberry fraction FC111 constituents separated and characterized by HPLC-DAD-MS.

From: In vitro and in vivo antibacterial activities of cranberry press cake extracts alone or in combination with β-lactams against Staphylococcus aureus

Peak tR(min)a λmax (nm)b MW (Da)c Putative identification Relative abundanced
1a,b 4.8   192 quinic acid  
Iridoids   
2a,b 6.5 235 390 monotropein 18.5 ± 0.78%
3 7.3 235 392 6,7-dihydromonotropein 26.8 ± 0.07%
16b 14.4 235 416 unknown monotropein derivative 54.8 ± 0.99%
     Total (vs. A254 nm) 22 %
Monophenolic acids
4 8.7 280 220 unknown benzoic acid derivative 3.1 ± 0.51%
5 8.9 280   unknown benzoic acid derivative 0.52 ± 0.06%
6 9.7 290 162 unknown benzoic acid derivative 0.78 ± 0.10%
7 9.8 290   unknown benzoic acid derivative 1.18 ± 0.11%
8 10.4 275 316 dihydroxybenzoic acid glycoside 3.45 ± 0.29%
9a,b 11.6 285, 320 342 caffeic acid glycoside 3.06 ± 0.45%
10 12.0 275 300 hydroxybenzoic acid glycoside 0.72 ± 0.16%
11 12.3 295, 305 326 coumaric acid glycoside isomer 1 14.04 ± 0.49%
12 12.4 275 238 unknown benzoic acid derivative 1.45 ± 0.049%
13 13.6 315 326 coumaric acid glycoside isomer 2 15.1 ± 0.40%
14 13.8 285, 310 326 coumaric acid glycoside isomer 3 16.1 ± 0.56%
15 14.1 295, 325   unknown hydroxycinnamic acid 7.22 ± 0.092%
16a 14.4 280 284 benzoyl-glycoside 5.44 ± 0.89%
17 14.7 285, 330 356 ferulic acid-glycoside 5.59 ± 0.21%
18 15.0 275   unknown benzoic acid derivative 13.24 ± 0.13%
19 15.3 280, 330 386 sinapinic acid-glycoside 7.47 ± 0.28%
20a,b 16.3 280   unknown benzoic acid derivative 1.50 ± 0.69%
     Total (vs. A254 nm) 9%
Anthocyanins
21 16.8 525 465 delphinidin-3-O-galactoside 0.40 ± 0.00%
24 18.0 518 449 cyanidin-3-O-galactoside 18.4 ± 0.01%
25 18.2 525 435 delphinidin-3-O-arabinoside 0.60 ± 0.03%
26 19.0 515 433 pelargonidin-3-O-galactoside 0.28 ± 0.00%
27 19.3 520 419 cyanidin-3-O-arabinoside 11.2 ± 0.00%
28 19.8 520 463 peonidin-3-O-galactoside 43.3 ± 0.03%
29 20.4 524 493 malvidin-3-O-galactoside 7.64 ± 0.00%
31 21.1 521 433 peonidin-3-O-arabinoside 15.5 ± 0.01%
33 21.6 530 463 malvidin-3-O-arabinoside 1.79 ± 0.00%
     Total (vs. A254 nm) 40%
Flavonols
30 20.5 370 450 myricetin-3-O-arabinoside 4.05 ± 0.34%
32 21.3 360 464 quercetin-3-O-galactoside 50.2 ± 0.11%
34 22.0 354 434 quercetin-3-O-xyloside 7.71 ± 0.00%
35 22.3 352 434 quercetin-3-O-arabinopyranoside 3.72 ± 0.02%
36 22.8 354 434 quercetin-3-O-arabinofuranside 13.65 ± 0.12%
37 23.3 352 448 quercetin-3-O-rhamnoside 2.87 ± 0.01%
38 23.6 356 478 isorhamnetin-3-O-galactoside 5.31 ± 0.04%
39 24.0 360 508 syringetin-3-O-galactoside 4.70 ± 0.05%
40 24.7 360   unknown flavonol derivative 0.46 ± 0.02%
41 25.0 355 448 isorhamnetin-3-O-arabinoside 1.55 ± 0.01%
42a,b 25.6 355 610 quercetin-3-O-(6”coumaroyl)-galactoside 2.27 ± 0.04%
43 26.1 355 478 syringetin-3-O-arabinoside 2.04 ± 0.04%
44 27.5 356 568 quercetin-3-O-(6” benzoyl)-galactoside 1.48 ± 0.02%
     Total (vs. A254 nm) 25%
  1. a tR , retention time of peak (measured in minutes).
  2. b λmax, refers to characteristic UV–VIS absorption maxima (nm) pertinent to identification.
  3. c MW, molecular weight (measured in Daltons).
  4. d Relative abundance reported as percentage with associated standard deviation (based on two separate HPLC runs); iridoids calculated vs. 254 nm; monophenolic acids calculated vs. 280 nm; anthocyanins calculated vs. 520 nm; flavonols calculated vs. 360 nm.
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us